



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



NOTICE IS HEREBY GIVEN that a meeting of the Board has been ordered and called for 9:00 am on Wednesday, August 16, 2023 at the Board office, for the purpose to wit:

AGENDA

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

Revised 08-10-2023

1. Call to Order
2. Invocation & Pledge of Allegiance
3. Quorum Call
4. Call for Additional Agenda Items & Adoption of Agenda
5. Consideration of Draft Minutes from Previous Meeting: [May 24, 2023](#)
6. Report on Action Items
7. Confirmation of Acts
8. Opportunity for Public Comment
 - A. [Letter](#) from Alliance for Pharmacy Compounding re USP <797> Regulatory Implementation
 - B. [Letter](#) from Kelly Parker with CE Broker/EverCheck/Immuwear
9. Special Orders of the Day
 - A. Presentation of Pharmacist Gold Certificate
 - (1) PST.010261 – Joel Seth Aronson
 - (2) PST.010295 – Severan Joseph Medine
10. Committee Reports
 - A. Finance – Mr. Resweber ([Committee Agenda](#))
 - (1) Presentation - Russ Champagne, CPA & Penny Scruggins, CPA with Champagne and Company
 - (2) Consideration of [Compiled Financial Statements for Fiscal Year 2022-2023](#)
 - B. Application Review – Dr. Cloud ([Committee Agenda](#))
 - (1) Consideration of Committee Recommendation re PHY.Applicant – Align Pharmacy, LLC
 - C. Reciprocity – Mr. Mannino
 - (1) [Pharmacists Licensed by Reciprocity](#)
 - D. Violations – Mr. Valentine
 - (1) Consideration of Proposed Voluntary Consent Agreements
 - a. Case No. 23-0072 ~ PHY.008214 – Baymark Health Services of Louisiana, Inc. *d/b/a* BAART Programs Alexandria
 - b. Case No. 23-0041 ~ PHY.005767 – Louisiana CVS Pharmacy, LLC *d/b/a* CVS Pharmacy #5544
 - c. Case No. 23-0103 ~ PHY.005831 – Louisiana CVS Pharmacy, LLC *d/b/a* CVS Pharmacy #0266
 - d. Case No. 22-0330 ~ PHY.004057 – Louisiana Walgreen Pharmacy, Inc. *d/b/a* Walgreen Pharmacy #4566

NOTE: Pursuant to the Open Meetings Law at R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a person, (2) strategy sessions or negotiations with respect to litigation, (3) discussions regarding the report, development, or course of action regarding security personnel, plans, or devices, including discussions concerning cybersecurity plans, financial security procedures, and assessment and implementation of any such plans or procedures, (4) investigative proceedings regarding allegations of misconduct, or other purposes itemized at La. R.S. 42:17.

NOTE: In compliance with Act 256 of the 2019 Louisiana Legislature, the Board gives public notice that any information submitted to the Board may become public record unless specifically exempted by the Public Records Law, R.S. 44:1 *et seq.*

NOTE: To request a disability accommodation, please contact Joe Fontenot, Executive Director, at 225.925.6496 or email at jfontenot@pharmacy.la.gov.

Louisiana Board of Pharmacy
Board Meeting Agenda – August 16, 2023

Page 2

- e. Case No. 23-0070 ~ PHY.005545 – Louisiana Walgreen Pharmacy, Inc. *d/b/a* Walgreen Pharmacy #09526
- f. Case No. 23-0059 ~ PHY.005593 – Louisiana Walgreen Pharmacy, Inc. *d/b/a* Walgreen Pharmacy #09753
- g. Case No. 23-0129 ~ PHY.007607 – Louisiana Walgreen Pharmacy, Inc. *d/b/a* Walgreen Pharmacy #19904
- h. Case No. 23-0086 ~ PHY.008107 - Pharmaceutical Specialties, LLC *d/b/a* Pharmaceutical Specialties
- i. Case No. 23-0087 ~ PST.016141 - Michael Marist Bourg
- E. Impairment – Ms. Hall ([Committee Agenda](#))
 - (1) Consideration of Committee Recommendations re Applications
- F. Reinstatement – Dr. Strong ([Committee Agenda](#))
 - (1) Consideration of Committee Recommendations re Applications
- G. Tripartite – Mr. LeBas
- H. Regulation Revision – Mr. Indovina
 - (1) Reconsideration of Regulatory Project 2023-02 ~ Temporary Closure of Pharmacy ([Draft #4](#))
 - (2) Consideration of Regulatory Proposal 2023-B ~ Product Integrity ([Draft #1](#))
 - (3) Consideration of Regulatory Proposal 2023-C ~ Automated Medication System (Draft [#2](#) & [#3](#))
 - (4) Consideration of Regulatory Proposal 2023-D ~ Prescription Monitoring Program ([Draft #1](#))
 - (5) Consideration of Regulatory Proposal 2023-E ~ Pharmacist Application ([Draft #1](#))
- I. Executive Committee – Mr. McKay ([Committee Agenda](#))
 - (1) Consideration of *Compliance Questionnaire* for Annual Legislative Financial Audit
 - (2) Consideration of *Annual Report*
 - (3) Consideration of Committee Recommendations from Committee Agenda Items
 - (4) *Exceptions Report*
- 11. Staff Reports
 - J. General Counsel – Mr. Finalet
 - (1) Consideration of Proposed Voluntary Consent Agreements & Surrenders
 - a. Case No. 23-0150 ~ PST.019134 – Albany Miranda Randall
 - b. Case No. 23-0164 ~ PST.024203 – Patrick Joseph LaBorde
 - c. Case No. 23-0175 ~ CPT.011169 – Casey Dawn Quebodeaux
 - d. Case No. 23-0180 ~ CPT.016892 – Jernesha Monica Holmes
 - e. Case No. 23-0193 ~ CPT.015675 – Cra’Jean Ja’Lynn Jasper
 - f. Case No. 23-0183 ~ CPT.011391 – Jason Paul Bergeron
 - g. Case No. 23-0194 ~ CPT.008174 – Leon Joseph Dion
 - h. Case No. 23-0199 ~ CPT.012069 – Lo Gillian Daleine Davidson
 - i. Case No. 23-0182 ~ CPT.013828 – Lakinya Sunja Farris

NOTE: Pursuant to the Open Meetings Law at R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a person, (2) strategy sessions or negotiations with respect to litigation, (3) discussions regarding the report, development, or course of action regarding security personnel, plans, or devices, including discussions concerning cybersecurity plans, financial security procedures, and assessment and implementation of any such plans or procedures, (4) investigative proceedings regarding allegations of misconduct, or other purposes itemized at La. R.S. 42:17.

NOTE: In compliance with Act 256 of the 2019 Louisiana Legislature, the Board gives public notice that any information submitted to the Board may become public record unless specifically exempted by the Public Records Law, R.S. 44:1 *et seq.*

NOTE: To request a disability accommodation, please contact Joe Fontenot, Executive Director, at 225.925.6496 or email at jfontenot@pharmacy.la.gov.

- j. Case No. 23-0201 ~ CPT.010994 – Joni Marcia LeDuff
 - k. Case No. 23-0187 ~ CPT.011959 – Danielle Marie Fontenot
 - l. Case No. 23-0200 ~ CPT.011029 – Kayla Renee’ Jones
 - m. Case No. 23-0236 ~ PST.023335 – Courtland Gregory Dickinson
 - n. Case No. 23-0235 ~ PST.019797 – Sharad Chandra Rai
 - o. Case No. 23-0196 ~ PST.022318 – Jack Michael McGuire
 - p. Case No. 23-0231 ~ CPT.012711 –Danielle Viola Scott
- K. Executive Director – Mr. Fontenot
- (1) Prescription Monitoring Program (PMP) – [Quarterly Report](#)
 - (2) Consideration of Requests for Waivers from PMP Reporting
 - (3) [New Laws](#) from 2023 Regular Session of Louisiana Legislature
 - (4) Credentials - [Census Report](#), [New Credentials Issued](#)
 - (5) Compliance Division – [Complaint Investigation Monitor](#)

12. New Agenda Items Added During Meeting

13. Announcements

14. Adjourn

NOTE: Pursuant to the Open Meetings Law at R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a person, (2) strategy sessions or negotiations with respect to litigation, (3) discussions regarding the report, development, or course of action regarding security personnel, plans, or devices, including discussions concerning cybersecurity plans, financial security procedures, and assessment and implementation of any such plans or procedures, (4) investigative proceedings regarding allegations of misconduct, or other purposes itemized at La. R.S. 42:17.

NOTE: In compliance with Act 256 of the 2019 Louisiana Legislature, the Board gives public notice that any information submitted to the Board may become public record unless specifically exempted by the Public Records Law, R.S. 44:1 *et seq.*

NOTE: To request a disability accommodation, please contact Joe Fontenot, Executive Director, at 225.925.6496 or email at jfontenot@pharmacy.la.gov .